Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer

[1]  K. Matsuo,et al.  Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer , 2014, Gastric Cancer.

[2]  N. Sugimoto,et al.  Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  I. Oh,et al.  Comparison of docetaxel/cisplatin dosages of 75/60 and 60/60 mg/m(2) for the treatment of non-small cell lung cancer. , 2012, Experimental and therapeutic medicine.

[4]  Hua Zhao,et al.  Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. , 2012, Gynecologic oncology.

[5]  A. Hinke,et al.  Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). , 2011, European journal of cancer.

[6]  D. Berry,et al.  High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  K. Matsuo,et al.  Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy , 2011, Cancer Chemotherapy and Pharmacology.

[8]  R. Milne,et al.  Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity , 2011, The Pharmacogenomics Journal.

[9]  K. Matsuo,et al.  Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Andreas Schneeweiss,et al.  Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Wesolowski,et al.  Is there a role for second-line chemotherapy in advanced gastric cancer? , 2009, The Lancet. Oncology.

[12]  K. Matsuo,et al.  Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. , 2009, European journal of cancer.

[13]  A. Schneeweiss,et al.  Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. Matsuo,et al.  Neutropenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. , 2009, Journal of Clinical Oncology.

[15]  S. Agelaki,et al.  Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. , 2008, Lung cancer.

[16]  V. Catalano,et al.  Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? , 2008, British Journal of Cancer.

[17]  D. Pezet,et al.  Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  T. Yamanaka,et al.  Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma , 2007, British Journal of Cancer.

[19]  H. Mouridsen,et al.  Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Eich,et al.  Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H. Gurney,et al.  How to calculate the dose of chemotherapy , 2002, British Journal of Cancer.

[22]  C. Blomqvist,et al.  Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF , 1999, British Journal of Cancer.

[23]  M. Gerretsen,et al.  L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives , 1994 .

[24]  D. Cruickshank,et al.  A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. , 1992, British Journal of Cancer.

[25]  J. Thigpen.  Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone , 2012 .

[26]  K. Matsuo,et al.  Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy. , 2010, Asian Pacific journal of cancer prevention : APJCP.

[27]  C. Hudis.  Intensive Dose-Dense Compared With Conventionally Scheduled Preoperative Chemotherapy for High-Risk Primary Breast Cancer: Untch M, Möbus V, Kuhn W, et al (Campus Berlin Buch, Germany; Klinikum Frankfurt Höchst, Germany; Bethesda Krankenhaus, Mönchengladbach, Germany; et al) J Clin Oncol 27:2938-294 , 2010 .

[28]  岸田 祐介.  Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer : results from Japan Multinational Trial Organization LC00-03 , 2010 .